Asset profile
KSP-0243
Small molecule
Evidence outlook · lead readout
NCT05831670 · Colitis, Ulcerative
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05831670: The trial randomized 108 participants to KSP-0243 or placebo with participants, clinicians, investigators, and outcome assessors masked. Its primary endpoint was clinical response based on the modified Mayo score at Week 8, but the registry does not report whether the comparison was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.